Home > Hepatitis C and injecting drug use: impact, costs and policy options.

Kretzschmar, Mirjam and Wiessing, Lucas and Jager, Johannes and Limburg, Wien and Postma, Maarten, eds. (2004) Hepatitis C and injecting drug use: impact, costs and policy options. EMCDDA Scientific Monograph Series; No. 7 Luxembourg: Office for Official Publications of the European Communities .

[img]
Preview
PDF (EMCDDA Monograph 7) - Published Version
1MB

Hepatitis C infections occurring in recent years in the European Union may cost countries billions of euros in future healthcare, according to research published in this monograph.

A conglomeration of state-of-the-art research on hepatitis C, drug use and public health methods, this publication presents analyses on the impact and costs of the disease among injecting drug users, as a basis for sound policy-making. Other issues addressed include: quality of life; treatment, surveillance and prevention; and the cost-effectiveness of measures such as needle-exchange programmes and substitution therapy.

Hepatitis C affects an estimated 170 million people worldwide and at least a million, but possibly several million, people in Western Europe who are at risk of developing liver cirrhosis or liver cancer. It is a highly infectious and potentially fatal blood-borne disease that attacks the liver and for which there is as yet no vaccine.

Table of contents
• Part I: Natural history, treatment, quality of life, epidemiology and prevention
• Part II: Models of hepatitis C in injecting drug users
• Part III: Healthcare costs of drug-related hepatitis C infection
• Part IV: Wider costs of drug use
• Part V: Cost-effectiveness of needle and syringe programmes and methadone maintenance


Item Type:Book
Date:2004
Call No:JB2.4, GH16.12.6.6, VH4
Pages:389
Publisher:Office for Official Publications of the European Communities
Corporate Creators:European Monitoring Centre for Drugs and Drug Addiction
Place of Publication:Luxembourg
ISBN:92-9168-168-7
Keywords:cost-effectiveness, cost-effectiveness of AOD health services, economic cost of AODU, Europe, hepatitis C, hepatitis C virus, methadone, methadone maintenance, needle disinfection, needle distribution and exchange
Notes:Includes tables, figures and bibliographic references.
EndNote:View
Accession Number:HRB 2807 (Available), HRB 2808 (Available)
Related URLs:
Subjects:T Demographic characteristics > Intravenous / injecting drug user
G Health and disease > Disorder by cause > Communicable disease
G Health and disease > Disorder by cause > Communicable disease > Hepatitis C
MP-MR Policy, planning, economics, work and social services > Policy > Policy on drugs and alcohol > Harm reduction policy
J Health care, prevention and rehabilitation > Health-related prevention > Health information and education > Communicable disease control
A Drugs and alcohol use, abuse, and dependence > Drugs and alcohol effects and consequences
J Health care, prevention and rehabilitation > Drugs and alcohol prevention > Drugs and alcohol use harm reduction

Repository Staff Only: item control page